@article{26550,
  author = {Lo N C and Bogoch I I and Blackburn B G and Coulibaly J T and N’Goran E K and Raso G and Becker S L and Abrams H B},
  title = {Comparison of community-wide, integrated mass drug administration strategies for schistosomiasis and soil-transmitted helminthiasis: a cost-effectiveness modelling study.},
  abstract = {<p>More than 1·5 billion people are affected by schistosomiasis or soil-transmitted helminthiasis. WHO's recommendations for mass drug administration (MDA) against these parasitic infections emphasise treatment of school-aged children, using separate treatment guidelines for these two helminthiases groups. We aimed to evaluate the cost-effectiveness of expanding integrated MDA to the entire community in four settings in Côte d'Ivoire.</p>

<h3>Methods</h3>

<p>We extended previously published, dynamic, age-structured models of helminthiases transmission to simulate costs and disability averted with integrated MDA (of praziquantel and albendazole) for schistosomiasis and soil-transmitted helminthiasis. We calibrated the model to data for prevalence and intensity of species-specific helminth infection from surveys undertaken in four communities in Côte d'Ivoire between March, 1997, and September, 2010. We simulated a 15-year treatment programme with 75% coverage in only school-aged children; school-aged children and preschool-aged children; adults; and the entire community. Treatment costs were estimated at US$0·74 for school-aged children and $1·74 for preschool-aged children and adults. The incremental cost-effectiveness ratio (ICER) was calculated in 2014 US dollars per disability-adjusted life-year (DALY) averted.</p>
},
  year = {2015},
  journal = {The Lancet. Global health},
  volume = {3},
  pages = {e629–e638 },
  url = {https://www.thelancet.com/pdfs/journals/langlo/PIIS2214-109X(15)00047-9.pdf},
  language = {eng},
}